# BridgeBio (BBOT) — Analyst Forecast

BBOT · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/bbot/forecast

## Analyst consensus

| Consensus | Buy | Hold | Sell | Analysts |
| --- | --- | --- | --- | --- |
| Buy | 10 | 0 | 0 | 10 |

## Price target

| Low | Average | High | Analysts |
| --- | --- | --- | --- |
| $15.00 | $22.00 | $27.00 | 6 |

Last price $2.95 (as of Oct 16, 2026).

## Recent analyst ratings

| Date | Firm | Action | Rating | Price target |
| --- | --- | --- | --- | --- |
| Sep 11, 2026 | JP Morgan | Maintained | Overweight | $23.00 |
| Sep 10, 2026 | Leerink Partners | Maintained | Outperform | $27.00 |
| Sep 9, 2026 | Wedbush | Maintained | Outperform | $25.00 |
| Sep 9, 2026 | Stifel | Maintained | Buy | $15.00 |
| Sep 9, 2026 | Raymond James | Maintained | Outperform | $22.00 |
| Sep 9, 2026 | Canaccord Genuity | Maintained | Buy | $20.00 |
| Aug 14, 2026 | JP Morgan | Maintained | Overweight | $25.00 |
| Jul 8, 2026 | JP Morgan | Initiated Coverage | Overweight | $27.00 |
| Jun 22, 2026 | Oppenheimer | Initiated Coverage | Outperform | $22.00 |
| May 11, 2026 | Canaccord Genuity | Initiated Coverage | Buy | $23.00 |
| Mar 6, 2026 | HC Wainwright & Co. | Maintained | Buy | $29.00 |
| Feb 11, 2026 | Stifel | Initiated Coverage | Buy | $23.00 |
| Jan 9, 2026 | Raymond James | Initiated Coverage | Outperform | $24.00 |
| Dec 11, 2025 | Wedbush | Maintained | Outperform | $25.00 |
| Dec 5, 2025 | Morgan Stanley | Initiated Coverage | Overweight | $20.00 |
| Nov 25, 2025 | Wedbush | Maintained | Outperform | $25.00 |
| Nov 13, 2025 | Oppenheimer | Maintained | Outperform | $22.00 |
| Sep 17, 2025 | Leerink Partners | Initiated Coverage | Outperform | $25.00 |
| Sep 15, 2025 | HC Wainwright & Co. | Initiated Coverage | Buy | $27.00 |
| Sep 4, 2025 | Oppenheimer | Initiated Coverage | Outperform | $23.00 |

## Frequently Asked Questions

### What is the price target for BBOT stock?

The average 12-month analyst price target for BridgeBio (BBOT) is $22.00, with a high estimate of $27.00 and a low of $15.00, across 6 analysts.

### Is BBOT a buy, sell, or hold?

Analysts covering BridgeBio currently average a Buy rating: 10 buy, 0 hold and 0 sell, from 10 analysts. Ratings reflect analyst opinion, not investment advice.

### What upside do analysts see for BBOT?

The average price target of $22.00 implies 645.76% upside from the last price of $2.95.

### What is the latest analyst rating on BBOT?

On Sep 11, 2026, JP Morgan maintained BridgeBio at Overweight with a price target of $23.00.

---

Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).